Ubs Group Ag Vaxxinity, Inc. Transaction History

Ubs Group Ag

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$0.62 - $0.86 $144 - $200	-233 Reduced 0.54%	42,787 $30,000
Q4 2023 Feb 09, 2024	BUY	$0.7 - $1.31 $23,559 - $44,089	33,656 Added 359.42%	43,020 $36,000
Q3 2023 Nov 09, 2023	SELL	$1.25 - $3.0 $19,508 - $46,821	-15,607 Reduced 62.5%	9,364 $12,000
Q2 2023 Aug 11, 2023	BUY	$1.73 - $2.79 $38,585 - $62,228	22,304 Added 836.3%	24,971 $62,000
Q1 2023 May 12, 2023	BUY	$1.43 - $4.24 $1,990 - $5,902	1,392 Added 109.18%	2,667 $6,000
Q4 2022 Feb 08, 2023	SELL	$1.31 - $2.62 $6,001 - $12,002	-4,581 Reduced 78.23%	1,275 $1,000
Q3 2022 Nov 10, 2022	BUY	$1.64 - $2.48 $9,603 - $14,522	5,856 New	5,856 $12,000
Q1 2022 May 16, 2022	SELL	$3.7 - $8.6 $9,494 - $22,067	-2,566 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$5.55 - $18.46 $14,241 - $47,368	2,566 New	2,566 $14,000

198K

Ticker VAXX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 112,150,000
Description
Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.